Louis Denis
Company: Verastem. inc
Job title: Chief Medical Officer
Seminars:
Introducing Rational Combinations of RAF/MEK Clamp Avutometinib: Breakthrough Designation & Beyond 2:45 pm
Presenting RAF/MEK clamp Avutometinib and FAK inhibitor Defactinib which are in clinical development in RAS/MAPK driven cancers, offering new hope for patients Demonstrating the potential for improved patient outcomes with registration-directed trial design and clinical development progress in low-grade serous ovarian cancer (LGSOC) and other RAS/ MAPK driven cancers Discussing future directions, including clinical trials…Read more
day: Day Two Track B PM